Study details
Enrolling now
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT IDNCT06903702ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
100
Study length
about 2.1 years
Ages
65+
Locations
7 sites in NJ, NY
What this study is about
This trial is testing whether allogeneic hematopoietic stem cell transplant, azacitidine and venetoclax, or maintenance therapy with azacitidine and venetoclax is more effective at preventing acute myeloid leukemia (AML) from returning.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Azacitidine (AZA)
- 2.Take Venetoclax
- 3.Undergo Allogeneic hematopoietic stem cell transplantation
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVsubcutaneous
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
azacitidine, venetoclax
Drug routes
injection, subcutaneous, oral
Endpoints
Primary: 1-year Relapse free survival (RFS)
Secondary: Overall survival (OS)
Body systems
Oncology